上世纪90年代开始，国际人类基因组用了10年时间，花了30亿美元，获得人类基因组，而今天，只需大约1000美元即可做完一个人的基因组测序，在深圳的华大基因研究院，这种测序一天可做1500例……成本的下降，带来的是基因测序走入寻常百姓家。这是记者在昨日举行的“大数据、大科学技术突破引发的新兴生物产业机遇”论坛上了解到的消息。

The 1990 s,The international human genome in ten years time,Spent 3 billion dollars,Get the human genome,And today,Only about 1000 dollars can finish a person's genome sequencing,In shenzhen huada gene research institute,The sequencing a day to do 1500 cases...A decline in the cost of,Bring is gene sequencing to ordinary people.This is a reporter in yesterday's"Large data/Big science technology breakthrough trigger new biological industry opportunities"BBS on understood.

　　首先解决“生死时速” It is the first thing to solve"Speed of life and death"

　　深圳华大基因研究院院长汪建指出，生物科学的发展首先要解决“生死时速”问题。他解释说，“就是让出生的人更健康，让生病的人可以活得更久。”

Shenzhen huada gene research institute President WangJian pointed out,The development of biological science first to solve"Speed of life and death"problems.He explained,"Born is to make people more healthy,Let the sick man can live longer."

　　生出一个先天缺陷的孩子，会给家庭和社会带来很大负担，在美国，有10%的家庭和出生缺陷有不同程度的关联。据统计，80%以上的出生缺陷与遗传相关，通过基因测序，可大大降低先天缺陷儿童的出生率。

Produce a congenital defect of children,Will give the family and social great burden,In the United States,10% of the families and birth defects have different degree of correlation.According to the statistics,More than 80% of the birth defects and genetic correlation,Through the gene sequencing,Can greatly reduce birth defects children's birth rate.

　　在肿瘤病的救治上，通过全基因组分析，肿瘤手术后复发的病例，可找到有效的药物靶点，进行药物治疗。“我们在肺癌患者中测出基因，运用过去治疗乳腺癌的药物，两周就可使肿瘤变小。”汪建指出，通过基因测序的靶向用药，未来3至5年内，可能有50%-70%的肿瘤是可以治疗的。

In the treatment of cancer,Through the whole genome analysis,Tumor recurrence after surgery cases,Can find effective drug targets,Drug therapy."We in lung cancer patients measure gene,Use the past drug treatment of breast cancer,Two weeks to make a smaller tumors."WangJian pointed out that,Through the gene sequencing of targeted drugs,The next 3 to 5 years,There may be 50% - 70% of the tumors can be treated.

　　临床需政策“绿色通道” Clinical need policy"Green channel"

　　新技术大量出现，可能与现行政策冲突。与会专家指出，基因等新技术临床应用，需要“绿色通道”。

New technologies have emerged,May and current policy conflict.The experts say,Gene and other new technology clinical application,need"Green channel".

　　中国科技管理研究院副院长朱岩梅展示了一张2011年全球500强企业的工业研发投入排名表，在前10名中，有5家和生物医药相关，但中国入围企业中，没有一家是生物领域的企业。她认为，“政策的制定者应该为创新前行者清除路上的障碍。”汪建认为，新产品临床推广还有很大障碍，要得到国家层面支持还需时间。

China science and technology management institute, vice President of the ZhuYanMei shows a 2011 global top 500 enterprises of industrial r&d investment league tables,In the first 10,Five home and biological medicine related,But China at enterprises,No one is in the field of biological enterprise.She thinks,"Policy makers should QianHangZhe clear the way for innovation barriers."WangJian think,New product clinical promotion also has the very big barrier,To get the national level support still need time.

　　苏格兰再生医学中心负责人、“克隆之父”伊恩·威尔默则提出，在干细胞治疗领域亟需开展国际合作，各国政府应该出台相关政策为干细胞治疗国际合作扫清障碍。

Scotland regenerative medicine center director/"The father of cloning"Ian wilmer is put forward,In the field of stem cell therapy need to carry out international cooperation,Governments should publish relevant policy for stem cell therapy for international cooperation obstacles.

　　大数据是大支撑 Big data is great support

　　阿里云计算资深技术专家蔡华指出，随着基因测序技术的成本降低，带来的是存储成本的上升，云计算将成为生物工业的基础设施。“大规模表示要存得下，低成本意味要用得起，这两者只能依赖云计算。” 蔡华指出，通过云计算的大数据处理，对资源进行削峰填谷，从而可达到低成本的目标。

Ali cloud computing senior technical experts CaiHua pointed out,Along with the gene sequencing technology cost reduction,Bring is storage costs rise,Cloud computing will become biological industrial infrastructure."Mass says to save to,Low cost means is used up,The two can only rely on cloud computing." CaiHua pointed out that,Through the cloud computing big data processing,To resources for peak clipping fill valley,Which can achieve the goal of low cost.

　　大数据也可解决生物制药的困惑。朱岩梅指出，过去60年，医药公司技术投入越来越多，重量级的发现却越来越少，如今不少国际大型医药公司和华大合作，利用基因测序、大数据来进行研发。遗憾的是，暂时还没有中国医药企业和华大合作研究药物。

Big data also can solve the puzzle of biological pharmacy.ZhuYanMei pointed out that,The past sixty years,Drug companies spend more and more technology,Heavyweight found but less and less,Now a lot of international large pharmaceutical companies and huada cooperation,Use of gene sequencing/Big data for research and development.It is a pity that,There is no Chinese medicine enterprise and huada cooperation study drug.

　　大数据也带来了研究成果的斐然，汪建在演讲中透露，两年来华大基因在《自然》、《科学》、《细胞》等全球级别最高的杂志上，共发表论文50篇，华大论文的平均引用率为98.3，我国的这个数据是6，全球是10，充分说明大数据和大科学的相关性。(记者 杨婧如 范京蓉)

Big data also brought brilliant achievements,WangJian said in his speech,Two years in China in large gene[natural]/[science]/[cell]At the global level, such as the highest magazine,Published article fifty,Huada paper average reference rate is 98.3,Our this data is 6,The global is ten,Fully shows the big data and the correlation of big science.(Reporter YangJingRu van Beijing rong)